Real-World Outcomes of Elacestrant in Patients With ESR1-Mutated Breast Cancer

SABCS 2024 - Breast Cancer Faculty Commentary
Videos
Erica L. Mayer, MD, MPH
Director of Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Boston, MA
Dr Erica Mayer comments on real-world outcomes for elacestrant derived from the GuardantINFORM database, and describes which patients elacestrant therapy may be best for.

Related Items

Imlunestrant, Alone or in Combination With Abemaciclib, Demonstrates Potential in Treating Advanced Breast Cancer
By Erica L. Mayer, MD, MPH
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2025 - ER+/HER2- Breast Cancer
SIM0270 Monotherapy and in Combination With Everolimus Shows Promise in Advanced Breast Cancer Treatment
By Erica L. Mayer, MD, MPH
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2024 - Breast Cancer Faculty Commentary
Study Demonstrates Elacestrant Benefit Is Maintained Regardless of ESR1 Mutation Levels
By Erica L. Mayer, MD, MPH
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2024 - Breast Cancer Faculty Commentary
Imlunestrant Shows Promise for Patients With ESR1-Mutated Advanced Breast Cancer
By Erica L. Mayer, MD, MPH
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2024 - Breast Cancer Faculty Commentary
Conference Coverage Proudly Presented by
CONQUER: the patient voice
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
The Oncology Nurse–APN/PA
The Oncology Pharmacist

Learn more about our family of publications.

View Our Publications


© Amplity, Inc. All Rights Reserved. Privacy Policy